Current treatment approach and future perspectives in B cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) are major mature B cell lymphomas.
• Advances in understanding tumor biology and molecular classification have identified new therapeutic targets.

Purpose of the Study:

• To review current treatment options for DLBCL and FL.
• To discuss treatment strategies for these lymphoma subtypes.
• To explore future perspectives in lymphoma treatment.

Main Methods:

• Literature review of treatment options for DLBCL and FL.
• Analysis of novel therapeutic approaches including targeted drugs and immunotherapies.
• Discussion of clinical decision-making factors for relapsed/refractory disease.

Main Results:

• Novel treatments like antibody-drug conjugates, Bruton tyrosine kinase inhibitors, CAR T-cell therapy, and bispecific antibodies have emerged.
• Current treatment selection relies on patient history, response duration, age, and frailty.
• Limited randomized trials exist for relapsed/refractory cases, and a unified prognostic index is lacking.

Conclusions:

• The treatment landscape for DLBCL and FL has significantly evolved.
• Personalized treatment strategies are needed, considering patient-specific factors and emerging therapies.
• Further research and clinical trials are crucial to optimize treatment selection and improve outcomes for patients with relapsed or refractory lymphoma.